(Nasdaq: MIRM), a leading rare disease company, today announced completion of enrollment in the Phase 3 AZURE-1 study and completion of screening in the Phase 3 AZURE-4 study, both evaluating ...
Microsoft Azure customers worldwide now gain access to Ryght's intelligent platform to take advantage of the scalability, reliability, and agility of Azure to drive application development and shape ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results